This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carnahan, J. Articles by Cesano, A. Search for Related Content PubMed PubMed Citation Articles by Carnahan, J. Articles by Cesano, A.

Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22

Characterization of in Vitro Properties¹

Amgen, Inc., Thousand Oaks, California 91320 [J. C., P. W., R. K., C. C., S. H., T. B., T. J., J. T., S. M., J. S., G. E., J. T., J. F., B. K., R. B., A. C.], and Center for Lymphoma and Myeloma and Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021 [J. P. L.]

Purpose: Epratuzumab is a novel humanized antihuman CD22 IgG1 antibody that has recently shown promising clinical activity, both as a single agent and in combination with rituximab, in patients with non-Hodgkin’s lymphomas (NHL). In an attempt to better understand the mode of action of epratuzumab, the antibody was tested in vitro in a variety of cell-based assays similar to those used to evaluate the biological activity of other therapeutic monoclonal antibodies, including rituximab. In this report, we present epratuzumab activities as they relate to binding, signaling, and internalization of the receptor CD22.

Methods: Chinese hamster ovary-expressed CD22 extracellular domain was used to measure epratuzumab affinity on Biacore. CD22 receptor density and internalization rate were measured indirectly using a monovalently labeled, noncompeting (with epratuzumab) anti-CD22 antibody on Burkitt lymphoma cell lines, primary B cells derived from fresh tonsils, and B cells separated from peripheral blood samples obtained from patients with chronic lymphocytic leukemia or healthy volunteers. Epratuzumab-induced CD22 phosphorylation was measured by immunoprecipitation/Western blot and compared with that induced by anti-IgM stimulation.

Results: Epratuzumab binds to CD22-extracellular domain, with an affinity of K_D = 0.7 nM. Binding of epratuzumab to B cell lines, or primary B cells from healthy individuals and patients with NHL, results in rapid internalization of the CD22/antibody complex. Internalization appears to be faster at early time points in cell lines than in primary B cells and NHL patient-derived B cells, but the maximum internalization reached is comparable for all B cell populations after several hours of treatment and appears to reach saturation at antibody concentrations of 1–5 µg/ml. Finally, epratuzumab binding results in modest but significant CD22 phosphorylation.

Conclusions: Epratuzumab represents an excellent anti-CD22 ligating agent, highly efficacious in inducing CD22 internalization, and can induce phosphorylation. Although we cannot unequivocally demonstrate here that epratuzumab-induced internalization and signaling of CD22 directly contribute to its therapeutic efficacy, these properties are the fundamental characteristics of the target CD22 and its interaction with epratuzumab. Similar results were observed when epratuzumab was tested in vitro on Burkitt B cell lines as well as on primary normal B cells and neoplastic B cells separated from fresh peripheral blood samples from patients with chronic lymphocytic leukemia.

This article has been cited by other articles:

				C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]

				E. A. Raetz, M. S. Cairo, M. J. Borowitz, S. M. Blaney, M. D. Krailo, T. A. Leil, J. M. Reid, D. M. Goldenberg, W. A. Wegener, W. L. Carroll, et al. Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study J. Clin. Oncol., August 1, 2008; 26(22): 3756 - 3762. [Abstract] [Full Text] [PDF]

				A M Jacobi, D M Goldenberg, F Hiepe, A Radbruch, G R Burmester, and T Dorner Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls Ann Rheum Dis, April 1, 2008; 67(4): 450 - 457. [Abstract] [Full Text] [PDF]

				P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s. [Abstract] [Full Text] [PDF]

				K. M. Haas, S. Sen, I. G. Sanford, A. S. Miller, J. C. Poe, and T. F. Tedder CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo. J. Immunol., September 1, 2006; 177(5): 3063 - 3073. [Abstract] [Full Text] [PDF]

				J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, et al. Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma J. Clin. Oncol., August 1, 2005; 23(22): 5044 - 5051. [Abstract] [Full Text] [PDF]

				J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al. Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results Clin. Cancer Res., August 15, 2004; 10(16): 5327 - 5334. [Abstract] [Full Text] [PDF]